Rethinking “Very High-Risk”: Prof. Karim Fizazi on PEACE-2 Results and the Evolution of Prostate Cancer Risk Stratification

Rethinking “Very High-Risk”: Prof. Karim Fizazi on PEACE-2 Results and the Evolution of Prostate Cancer Risk Stratification

2026.02.28
During a recent major international oncology congress, Professor Karim Fizazi from the University of Paris-Saclay (Gustave Roussy) presented the first results of the Phase III PEACE-2 trial. This study evaluated whether the addition of cabazitaxel and/or pelvic radiotherapy to the standard of care—androgen deprivation therapy (ADT) combined with prostate radiation—improves outcomes in patients with very high-risk localized prostate cancer.
Combination Therapy Breakthrough Exceeds 5 Years OS! BRCAaway Trial Establishes the Core Role of Abiraterone + Olaparib in BRCA-Mutated mCRPC

Combination Therapy Breakthrough Exceeds 5 Years OS! BRCAaway Trial Establishes the Core Role of Abiraterone + Olaparib in BRCA-Mutated mCRPC

2026.02.28
At a recent major oncology academic conference, Professor Maha Hussain from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago presented the latest efficacy and overall survival (OS) data from the BRCAaway trial (Abstract 16). This Phase II clinical trial thoroughly investigated the definitive efficacy and safety profile of abiraterone combined with olaparib versus either agent alone as a first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring DNA repair defects.
Dr. Martin Gleave Deciphers GUNS Study: Triplet Therapy Significantly Increases MRD Rates in Genomically Aggressive Prostate Cancer

Dr. Martin Gleave Deciphers GUNS Study: Triplet Therapy Significantly Increases MRD Rates in Genomically Aggressive Prostate Cancer

2026.02.28
At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (GU ASCO), Dr. Martin Gleave from the University of British Columbia presented the latest data from the GUNS study (Genomic Umbrella Neoadjuvant Study). The presentation focused on the pathological responses of high-risk prostate cancer (PCa) patients with aggressive genomic alterations treated with neoadjuvant androgen receptor pathway inhibitor (ARPI) triplet versus doublet regimens.
Balancing Efficacy and Well-being: PRO Dynamics and Skeletal Safety in the Phase 3 PSMAddition Trial for mHSPC

Balancing Efficacy and Well-being: PRO Dynamics and Skeletal Safety in the Phase 3 PSMAddition Trial for mHSPC

2026.02.28
At a recent international oncology symposium, Michael Morris, MD, from Memorial Sloan Kettering Cancer Center (MSKCC), delivered an in-depth academic report on Abstract #18. The presentation focused on the latest data regarding health-related quality of life (HRQoL), pain, and symptomatic skeletal events (SSE) from the Phase 3 PSMAddition study. This trial evaluates the efficacy and safety of 177Lu-PSMA-617 in combination with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) for patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). Below is a summary of the core findings.
EBRT vs. Brachytherapy Boost in Localized Prostate Cancer: In-Depth Analysis of 15-Year OS and PCSM Data from the ASCENDE-RT Trial

EBRT vs. Brachytherapy Boost in Localized Prostate Cancer: In-Depth Analysis of 15-Year OS and PCSM Data from the ASCENDE-RT Trial

2026.02.28
At a recent international oncology conference, Professor Scott Tyldesley from Vancouver, Canada, delivered an oral presentation on behalf of Professor Jim Morris, sharing the 15-year long-term survival analysis of the ASCENDE-RT trial (Abstract No. 306). This study compared the long-term overall survival (OS) and prostate cancer-specific mortality (PCSM) of an external beam radiotherapy (EBRT) boost versus a low-dose-rate (LDR) brachytherapy boost in patients with localized prostate cancer. Oncology Frontier (Mediamedic) has summarized the core academic highlights to share with our readers.
Neoplasia | Teams Led by Jianxiang Wang and Shaowei Qiu Reveal Prognostic Heterogeneity in FLT3-ITD–Mutated AML: Clonal Origin and 13q UPD as Key Drivers

Neoplasia | Teams Led by Jianxiang Wang and Shaowei Qiu Reveal Prognostic Heterogeneity in FLT3-ITD–Mutated AML: Clonal Origin and 13q UPD as Key Drivers

2026.02.25
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy. Approximately 20–30% of AML patients harbor FLT3 internal tandem duplication (FLT3-ITD) mutations. FLT3-ITD is a major driver mutation in AML and typically arises as a late genetic event during leukemogenesis, often coexisting with mutations in NPM1, DNMT3A, WT1, and others. Although FLT3-ITD is generally associated with poor prognosis, substantial variability in clinical outcomes has been observed among FLT3-ITD–positive patients. Previous studies have largely focused on the molecular characteristics of FLT3-ITD itself, while the impact of its clonal origin on prognosis has been underexplored. Moreover, the key genetic evolutionary mechanisms driving resistance during progression from newly diagnosed disease to relapsed/refractory (R/R) AML remain incompletely understood.
Professor Wang Sanbin: Advancing Integrative Rehabilitation and Translating Cutting-Edge Therapies in Lymphoma Care

Professor Wang Sanbin: Advancing Integrative Rehabilitation and Translating Cutting-Edge Therapies in Lymphoma Care

2026.02.25
From November 6 to 9, 2025, the China Conference on Holistic and Integrative Oncology (CCHIO 2025) was grandly convened in Kunming. As one of China’s largest and most influential oncology meetings, the conference gathered many leading national and international oncology experts to explore the latest advances and future directions in cancer prevention and treatment through the lens of integrative medicine. The event provided a high-level platform for strengthening China’s cancer diagnosis and treatment system.
Professor YanminZhao: A New Management Framework for TP53 Mutations — From MRD Monitoring to Emerging Treatment Strategies | 2025 International Cell & Immunotherapy Congress

Professor YanminZhao: A New Management Framework for TP53 Mutations — From MRD Monitoring to Emerging Treatment Strategies | 2025 International Cell & Immunotherapy Congress

2026.02.25
mmunotherapy field, enhance communication on key scientific issues, share the latest clinical advances, and foster global collaboration and translational progress, the 2025 International Cell & Immunotherapy Congress (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), Zhejiang Immunological Society and Zhejiang Anti-Cancer Association—was held on November 13–16, 2025 in Hangzhou, China, and co-hosted by the First Affiliated Hospital of Zhejiang University School of Medicine and the Liangzhu Laboratory.
Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

2026.02.09
Recently, the upper urinary tract reconstruction team led by Xuesong Li, Director of the Department of Urology at Peking University First Hospital, successfully performed a domestic surgical robot–assisted laparoscopic fully intracorporeal autologous kidney transplantation for a patient with complex upper urinary tract obstruction.
Breast Cancer Chronicle · 2025 Professor Shusen Wang: Advances in Endocrine Therapy for HR+/HER2− Advanced Breast Cancer — Approval of Inavolisib-Based Combinations and New Pathways Opened by the evERA BC Study

Breast Cancer Chronicle · 2025 Professor Shusen Wang: Advances in Endocrine Therapy for HR+/HER2− Advanced Breast Cancer — Approval of Inavolisib-Based Combinations and New Pathways Opened by the evERA BC Study

2026.02.09
The evolution of breast cancer diagnosis and treatment is an epic journey spanning past and present, marked by breakthroughs that have profoundly changed patient outcomes. From January 9 to 11, 2026, the Northern China Breast Cancer Salon · Annual Progress Review was held in Beijing. One of the most anticipated sessions was the Annual Review of Advances in Breast Cancer Therapy, which brought together leading experts to focus on the most significant international and domestic developments of 2025. Topics ranged from surgery, pathology, and radiotherapy to molecular classification and subtype-specific treatment, with in-depth discussion and synthesis of research that has reshaped clinical practice.